HEIDELBERG, Germany, May 17 /PRNewswire/ -- LION bioscience AG (Neuer Markt: LIO, WKN 504 350, Nasdaq: LEON) today announced that it has granted a license for LION's data integration system SRS to Affymetrix, Inc. (Nasdaq: AFFX - news) to build a web portal for its customers as well as for internal use. The web portal will supply detailed information relating to Affymetrix's GeneChip® probe arrays and related products. This new application of SRS as a web portal follows its prominent application for the Celera Discovery System(TM)(CDS) and further demonstrates the outstanding position of LION's SRS system in supplying scientific data and information. SRS integrates diverse data through one interface and is the basis for LION's enterprise-wide R&D knowledge management solutions i-biology®.
``With LION's proven success in the market and LION's expertise with portals based on SRS, we can now provide our customers with a state-of-the-art system to access supporting information for their research,'' said David Craford, Vice President of Marketing, Instrumentation and Informatics. ``Affymetrix's new web portal will offer our customers added value and enable them to more rapidly understand biological functions of genes analyzed using our expression arrays, and thus resulting in the acceleration of new discoveries.''
LION's SRS system integrates more than 400 diverse databases. It is currently used by more than 50 commercial customers and more than 100 academic institutions worldwide. SRS is at the heart of LION's Life Science Informatics solutions, integrating diverse data throughout the entire R&D process. Affymetrix's portal is expected to provide access to a wide range of biological data including genomes, genes, transcripts, proteins, and literature annotation. SRS also serves as a web portal for the Celera Discovery System(TM) (CDS) established in March 2000, which allows rapid access to drosophila and human genome data; the web portal of Scientific World, established in January 2000 supplies data from scientific literature via the Internet.
``Affymetrix's use of the SRS technology for its web portal and its own research reinforces our leading position and increases our visibility in the rapidly expanding market of expression profiling,'' said Dr. Jan Mous, Chief Scientific Officer of LION bioscience. ``In addition to Celera's CDS and other applications, the Affymetrix portal is yet another commercial application of the unique integration capabilities of SRS for rapid information access. This supports LION's outstanding position in the market and strengthens the position of SRS as the standard integration platform for diverse data in the market.''
About LION bioscience AG:
LION bioscience (http://www.lionbioscience.com) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. These solutions integrate all R&D disciplines, spanning from genetics to early and late discovery through clinical trials. LION offers these solutions via two primary lines of business:
-- i-biology®: the installation and implementation of enterprise-wide
horizontal information and knowledge management solutions as part of
LION's Life Science Informatics (LSI(TM)) line of business; and
-- Integrated Drug Discovery and Diagnostics (iD3(TM)): application of
i-biology® to LION's internal drug discovery program with the goal to
out-license specific databases, polymorphism marker panels, and
validated targets and leads.
Founded in 1997, LION, together with its consolidated subsidiaries, has more than 440 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK, Cambridge, MA, USA and San Diego, CA, USA. To date, LION has established partnerships with leading life science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, Glaxo Wellcome, GMD, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, SmithKline Beecham, Sumitomo Pharmaceuticals and Tripos. |
